Amarin Corporation plc: PharmaVitae Report

• Publication date: June 2012
• Report size: 31 pages

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Analysis...

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.Analysis of AMR101 and how it compares with Pronova/GlaxoSmithKline’s omega-3 fatty acid product LovazaDiscussion of the company's strategy, commercial relationships, and forthcoming catalystsSales forecasts through to 2017Financial analysis of the company, including operating performance forecasts through to 2017This report provides forecasts and analysis of Amarin's AMR101. AMR101 is currently being evaluated by the FDA for patients with very high triglycerides, with an expected PDUFA date of July 26, 2012. Amarin also expects to file the drug for approval in patients with high triglycerides in combination with statins within the next year.Analyze how the performance of AMR101 will shape Amarin’s growth prospectsUnderstand the current and future market for omega-3 fatty acid agents and how AMR101 will compete for shareAssess Amarin’s potential to partner with another company for the marketing of AMR101

Electronic Component And Semiconductor Industry